# T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

> **NCT02442297** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 10 (actual)

## Conditions studied

- Brain Tumor, Recurrent
- Brain Tumor, Refractory

## Interventions

- **BIOLOGICAL:** HER2-specific T cells

## Key facts

- **NCT ID:** NCT02442297
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-04-01
- **Primary completion:** 2022-04-27
- **Final completion:** 2037-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442297, "T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02442297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*